9390 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858 779 3100
https://poseida.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 330
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Mark J. Gergen J.D. | Executive Chairman of the Board | 961.8k | N/A | 1963 |
Dr. Kristin Yarema Ph.D. | President, CEO & Director | 711.99k | N/A | 1971 |
Ms. Johanna M. Mylet CPA | Chief Financial Officer | N/A | N/A | 1988 |
Mr. Loren Wagner | Chief Operations Officer | N/A | N/A | N/A |
Ms. Kristin Martin | Chief People & Administration Officer | N/A | N/A | N/A |
Mr. Alexander Chapman | Senior VP of Investor Relations & Corporate Communications | N/A | N/A | N/A |
Mr. Harry J. Leonhardt Esq., J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary | 630.23k | N/A | 1957 |
Dr. Devon J. Shedlock Ph.D. | Chief Scientific Officer of Cell Therapy | N/A | N/A | N/A |
Ms. Lisa Portale | Senior Vice President of Regulatory Affairs | N/A | N/A | N/A |
Dr. Jeffrey W. Winkelman J.D., Ph.D. | Senior VP & Chief Patent Counsel | N/A | N/A | N/A |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
Poseida Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 8. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 8; Compensation: 9.